Ardy Arianpour is CEO & Co-Founder of Seqster, a data-driven healthcare SaaS platform that seamlessly integrates into any payer, provider, or clinical research enterprise. Seqster provides instant interoperability to retrieve and harmonize electronic health records (EHR), genetic, and continuous monitoring data from distinct sources. Ardy is a visionary health tech executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and SVP of Ambry Genetics that sold to Konica for $1B in 2017. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardyplayed an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management.
If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.